V I N I : The significant rate of nonresponders to cardiac resynchronization therapy (CRT) prompts the need for better noninvasive prediction tools for identifying those who may benefit from CRT. 
diameter, and New York Heart Association functional class IV) and myocardial viability also have an influence.
V I C I : With the incorporation of electrocardiographic, mechanical and clinical features, prediction tools to identify responders to CRT continue to become more sophisticated. The derivation or validation of a risk prediction score is likely to be an important next step in choosing appropriate candidates for this intervention, as is confirmation in a multicenter trial. The bedside cardiac physical examination provides important preliminary data, which determines whether additional testing is required for most patients presenting to the cardiology clinic or in the hospital. However, improvements in portable imaging technology now provide a readily accessible alternative to the physical exam that may be more standardized and less susceptible to error.
V I D I :
In this observational study of 250 patients, handheld ultrasound provided a more accurate diagnosis than physical examination for the majority of common cardiovascular abnormalities and led to a projected cost savings of about $63.00 per patient.
V I C I : With less emphasis being placed on the cardiac physical examination and the advent of newer technologies, such as the handheld ultrasound, the physical examination is quickly becoming a dying art.
Additional studies are needed to determine whether the use of such portable imaging modalities, which may be able to detect disease more effectively than the physical exam, improve long-term survival and prove to be cost-effective in the long-term. The evolution of cardiac magnetic resonance protocols has allowed for an improved ability to better characterize differences in diastolic function. Such subtle differences can be especially important in disease states such as systolic heart failure (SHF) and heart failure patients with preserved ejection fraction (HFpEF), where pathophysiologic differences can influence prognosis and management.
V I D I : Using cardiac magnetic resonance T1 mapping technique to quantify diffuse myocardial fibrosis in 40 patients with SHF, 62 patients with HFpEF, and 22 patients without heart failure, the authors report that diffuse myocardial fibrosis was significantly associated with diastolic function in HFpEF but not in SHF.
V I C I : The ability to provide detailed in vivo tissue characterization using extracellular volume fraction quantification provides an important tool for determining preclinical diastolic dysfunction in heart failure.
Future studies will, without a doubt, assess the additional prognostic information added by this information and whether therapies aimed at reverse remodeling, such as angiotensin-converting enzyme inhibitors, can be begun even earlier based on cardiac magnetic resonance abnormalities. Female sex independently associated with coronary atheroma regression. There was a significant interaction between sex and treatment specification, with rosuvastatin-treated women demonstrating the greatest degree of plaque regression. For on-treatment low-density lipoprotein-cholesterol levels below 70 mg/dl, women demonstrated greater coronary atheroma regression than their male counterparts.
V I C I : Although the overall parent study was negative with respect to differences in clinical outcomes, this substudy of SATURN adds further evidence to the growing body of literature that there may be sexspecific differences in response to statin therapy. It raises the question of whether additional prospective statin trials, powered for outcomes, are needed in women.
